DAFNA Capital Management’s Neurogene NGNE Stock Holding History

DAFNA Capital Management’s Portfolio NGNE Stock Details NGNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.14M	Buy	56,635 +28,661	+102%	+$555K	0.26%	56
2025 Q4	$576K	Sell	27,974 -2,401	-8%	-$59.8K	0.13%	67
2025 Q3	$526K	Sell	30,375 -20,721	-41%	-$416K	0.13%	68
2025 Q2	$764K	Sell	51,096 -404	-0.8%	-$6.34K	0.21%	61
2025 Q1	$603K	Hold	51,500	–	–	0.17%	69
2024 Q4	$1.18M	Buy	51,500 +43,725	+562%	+$1.63M	0.3%	54
2024 Q3	$326K	Sell	7,775 -3,225	-29%	-$125K	0.08%	77
2024 Q2	$400K	Buy	+11,000	New	+$388K	0.1%	74
2018 Q2	–	Sell	-5,396	Closed	-$1.52M	–	78
2018 Q1	$1.52M	Sell	5,396 -550	-9%	-$152K	0.74%	39
2017 Q4	$1.4M	Buy	5,946 +1,969	+50%	+$461K	0.75%	40
2017 Q3	$1.13M	Buy	+3,977	New	+$1.14M	0.7%	42
2016 Q4	–	Sell	-1,000	Closed	-$267K	–	70
2016 Q3	$267K	Buy	+1,000	New	+$202K	0.19%	63

Other funds holding NGNE

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

DAFNA Capital Management's NGNE Position: Q1 2026 in Review

DAFNA Capital Management increased its Neurogene (NGNE) stake by 102% in Q1 2026, buying an estimated $555K and bringing the position to 56,635 shares worth $1.14M. The position accounts for 0.26% of the portfolio, ranked #56.

DAFNA Capital Management first reported a position in NGNE in Q3 2016 and has held it in 12 quarters since. The position peaked at $1.52M in Q1 2018. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

DAFNA Capital Management held 56,635 shares of Neurogene worth $1.14M as of Q1 2026.
DAFNA Capital Management bought 28,661 Neurogene shares in Q1 2026, an estimated $555K.
Neurogene made up 0.26% of DAFNA Capital Management's portfolio in Q1 2026, its #56 holding.
DAFNA Capital Management first reported a position in Neurogene in Q3 2016 and has held it in 12 quarters since.
DAFNA Capital Management's Neurogene position peaked at $1.52M in Q1 2018.
96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.